Hospira gets the OK from FDA for azithromycin injection

LAKE FOREST, Ill. Hospira, the world leader in generic injectable pharmaceuticals, announced the Food and Drug Administration has approved its 500 mg vial of azithromycin for injection in the ADD-Vantage System.

ADD-Vantage is a specially designed, two-part system that does not require clinicians to use a needle and syringe to mix the drug and the solution. This reduces the risk of accidental needlesticks, enhances workflow and can result in less waste due to stability and shelf-life factors.

"Hospira is the first company to offer azithromycin in an advanced drug delivery system," said Joshua Gordon, VP specialty pharmaceuticals at Hospira. "This reinforces Hospira's commitment to healthcare worker safety, as well as to providing safe and effective generic drugs to patients."

Hospira offers approximately 200 generic injectable drugs in several dosages and formulations, as well as a variety of formats.